Helping people age healthier and lower Alzheimer's risk
Official title: Longevity Consortium
Funded at Translational Genomics Research Inst · NIH-11195694 · Data updated 2026-11-12
Teams combine decades of human data, lab tests, and animal work to find markers and targets that could help people live longer and reduce Alzheimer's risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | September 30, 2004 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $8,740,512 |
| NIH project number | 5U19AG023122-17 |
| Project ID | NIH-11195694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are older adults (including very old individuals and those with or at risk for Alzheimer’s) who can provide health information and biological samples or take part in follow-up visits.
✕Less likely to help
Children, people with acute unrelated illnesses, or anyone expecting an immediate personal treatment benefit are unlikely to gain direct clinical benefit from participation.
What this research studies
This consortium brings together many studies, diverse human groups (including very old adults), laboratory assays, and animal or cell models to look for consistent signs of healthier aging and resistance to Alzheimer's. Five linked projects will generate new data while an Integrated Analysis Core will combine results across projects to highlight the most promising biomarkers and targets. The effort uses shared data, assays, and long-term follow-up so findings seen across different approaches are more likely to matter for people. Depending on the project, participants may be asked to share health histories, biological samples, or take part in follow-up visits.
Why it matters
Potential benefit: If successful, the work could identify biomarkers, prevention targets, or intervention strategies that improve healthy aging and lower Alzheimer’s risk.
How similar studies have gone: Large consortia (for example ADNI and long-term longevity cohorts) have produced useful biomarkers and insights, but this highly integrated, cross-species approach is broader and relatively novel.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Schork, Nicholas Joseph — Translational Genomics Research Inst
- Study coordinator: Schork, Nicholas Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.